Should You Sell Your Medical Practice to Private Equity? A 2026 Decision Framework

TL;DR: Private equity continues to be the most active buyer of US physician practices in 2026, particularly in dermatology, ophthalmology, orthopedics, GI, and primary care. A PE sale can unlock 6–10× EBITDA valuations and meaningful liquidity, but it permanently alters governance, autonomy, and brand. The right answer depends on five questions every physician-owner should answer honestly before going to market.

---

The 2026 PE-in-Healthcare Landscape

Despite tighter credit and elevated regulatory scrutiny, private equity remains the dominant force in physician-practice M&A:

PE-backed platforms continue to roll up sub-specialty practices in dermatology, ophthalmology, GI, orthopedics, urology, ENT, and primary care

Hospital systems remain active but typically pay lower multiples than PE

Independent physician acquirers are a real but shrinking option as fewer young physicians want ownership (related insight)

For a healthy practice with $2M+ EBITDA, PE valuations in 2026 commonly land in the 6× to 10× EBITDA range, with the highest multiples reserved for platforms (vs. tuck-ins) and for specialties with strong organic-growth and ancillary-revenue stories.

Pros of Selling Your Medical Practice to Private Equity

Immediate liquidity , typically 60–80% of enterprise value at close, with the remainder rolled as equity

Multiple expansion , small practices often sell at 4–5× EBITDA standalone but inherit the platform's 10–14× multiple on rollover equity ("second bite of the apple")

Infrastructure , centralized HR, IT, RCM, marketing, and procurement

Capital access , funding for new providers, locations, and equipment

Risk transfer , payer contracting and compliance risk shifts to a larger balance sheet

Cons of Selling Your Medical Practice to Private Equity

Loss of autonomy , strategic, financial, and often clinical workflow decisions move to the platform

Cultural change , staffing, scheduling, and patient-experience standards typically shift toward platform norms

Compensation restructure , most deals reset physician compensation models, often lowering W-2 income in exchange for equity

Exit risk , your rollover equity is only as valuable as the platform's next recapitalization

Reputation considerations , patients and referring physicians are increasingly aware of (and sometimes sensitive to) PE ownership

The 5-Question Decision Framework

Before you engage a banker, answer these honestly:

1. What problem is the sale actually solving?

Liquidity, succession, burnout, growth capital, and risk transfer are all legitimate, but they lead to different deal structures. Be explicit about the primary driver.

2. What is your 10-year horizon?

If you plan to practice 10+ more years, a PE sale fundamentally changes the next decade of your career. If you plan to retire in 3–5, the calculus is mostly financial.

3. Is your practice actually sellable today?

Clean financials, low founder-dependency, documented processes, and >$1.5M EBITDA are the table stakes. Most practices need 12–24 months of readiness work before going to market.

4. Do you understand your full buyer universe?

PE is one option. Hospital systems, payer-owned platforms, larger independent groups, and individual physicians are all real buyers, and the right structure for you may not be the PE structure.

5. Who is at the table negotiating for you?

The buyer has a banker, a lawyer, and a quality-of-earnings team. If you don't have equivalent representation, including sell-side advisory experienced in physician practices, you are at a structural disadvantage.

How to Maximize Valuation Before a PE Sale

Practices that command the highest multiples share traits any owner can build toward:

Three years of clean, auditable financials with personal expenses fully separated

Documented SOPs for clinical and administrative workflows

Diversified revenue , not concentrated in one provider, payer, or service line

Strong, retainable management team below the owner

Growth story , recent additions of providers, locations, or ancillary services

Defensible payer contracts at or above market rates

PMC's M&A advisory team routinely runs 12–24 month readiness programs that lift exit multiples 1–3 turns of EBITDA.

Frequently Asked Questions

Should I sell my practice to private equity?

You should consider it seriously if you want partial liquidity now, infrastructure support, and a defined path to a future exit, and you are comfortable trading autonomy for those benefits. You should think twice if your primary motivation is short-term cash without a clear post-sale plan.

What are the pros and cons of selling a medical practice to PE?

Pros: immediate liquidity, multiple expansion via rollover equity, infrastructure, capital access, risk transfer. Cons: loss of autonomy, cultural change, compensation restructure, exit dependency on the platform's next recap, and patient/referrer perception risk.

What multiple does private equity pay for a medical practice in 2026?

Most physician-practice PE transactions in 2026 close between 6× and 10× EBITDA, with platforms commanding the top of the range and tuck-ins the bottom. Specialty, scale, growth, and quality of earnings drive variance.

How long does a PE sale process take?

Typically 6–12 months from engaging an advisor to close, plus the recommended 12–24 months of pre-market readiness for practices that want top-quartile outcomes.

Can I sell only part of my practice to private equity?

Yes. Most physician PE transactions are partial sales, owners commonly sell 60–80% and roll the rest as equity in the platform.

---

Thinking about whether a PE sale is right for your practice? Schedule a confidential discovery call, we'll pressure-test the decision against your specific numbers, timeline, and goals before you ever talk to a banker.

Should You Sell Your Medical Practice to Private Equity? A 2026 Decision Framework